INmune Bio Inc INMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
INmune Bio to Attend the 2026 Maxim Growth Summit
Trading Information
- Previous Close Price
- $1.18
- Day Range
- $1.20–1.20
- 52-Week Range
- $1.10–2.60
- Bid/Ask
- $1.17 / $1.21
- Shares Outstanding
- 30.96M
- Market Cap
- $38.85M
- Volume/Avg
- 2,556 / 327,003
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.inmunebio.com
Valuation
Metric | INMB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | INMB |
|---|---|
Quick Ratio | 6.19 |
Current Ratio | 6.41 |
Interest Coverage | — |
Quick Ratio
INMB
Profitability
Metric | INMB |
|---|---|
Return on Assets (Normalized) | −33.50% |
Return on Equity (Normalized) | −43.81% |
Return on Invested Capital (Normalized) | −41.39% |
Return on Assets
INMB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<?TNf>k | LOCK|qJPS | $138B | |||
| Moderna Inc MRNA | LOCK|#Tyb%? | LOCK|J^ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|@%$&m%h | LOCK|>MFF | $93B | |||
| argenx SE ADR ARGX | LOCK|b%#&t$ | LOCK|@M? | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Zl&X#% | LOCK|Z% | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|mVVFTr@h | LOCK|?g@n | $30B | |||
| Incyte Corp INCY | LOCK|@Fq>%^> | LOCK|&w | $24B | |||
| BioNTech SE ADR BNTX | LOCK|zK<?<v> | LOCK|&!z | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<Q!g!W! | LOCK|$Z>VW | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|@Wc>?t | LOCK|Ds | $15B |
United States